DE60226327D1 - Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin - Google Patents

Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Info

Publication number
DE60226327D1
DE60226327D1 DE60226327T DE60226327T DE60226327D1 DE 60226327 D1 DE60226327 D1 DE 60226327D1 DE 60226327 T DE60226327 T DE 60226327T DE 60226327 T DE60226327 T DE 60226327T DE 60226327 D1 DE60226327 D1 DE 60226327D1
Authority
DE
Germany
Prior art keywords
globulin
medicine
product
product obtained
cleaning process
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60226327T
Other languages
English (en)
Other versions
DE60226327T2 (de
Inventor
Charlotte Svaerke Jorgensen
Inga Laursen
Gunnar Houen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Application granted granted Critical
Publication of DE60226327D1 publication Critical patent/DE60226327D1/de
Publication of DE60226327T2 publication Critical patent/DE60226327T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DE60226327T 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin Expired - Fee Related DE60226327T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101217 2001-08-14
DK200101217 2001-08-14
PCT/DK2002/000531 WO2003016348A2 (en) 2001-08-14 2002-08-12 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine

Publications (2)

Publication Number Publication Date
DE60226327D1 true DE60226327D1 (de) 2008-06-12
DE60226327T2 DE60226327T2 (de) 2009-07-09

Family

ID=8160667

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226327T Expired - Fee Related DE60226327T2 (de) 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Country Status (9)

Country Link
EP (1) EP1419177B1 (de)
JP (1) JP2005508892A (de)
AT (1) ATE393780T1 (de)
AU (1) AU2002321012B2 (de)
CA (1) CA2456843A1 (de)
DE (1) DE60226327T2 (de)
DK (1) DK1419177T3 (de)
ES (1) ES2305272T3 (de)
WO (1) WO2003016348A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5112060B2 (ja) * 2004-06-29 2013-01-09 リライアンス ライフ サイエンシーズ プライベイト リミテッド ウイルス安全性生物学的流体の調製のための方法
CN100354301C (zh) * 2005-10-13 2007-12-12 南京工业大学 化学合成多肽的新型大规模分离制备技术
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
BR112012030530A2 (pt) * 2010-05-18 2022-12-20 Abbvie Inc Aparelho e processo para purificação de proteínas
WO2012029954A1 (ja) 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
EP2682168A1 (de) 2012-07-02 2014-01-08 Millipore Corporation Reinigung biologischer Moleküle
EP3081221B1 (de) * 2013-12-13 2021-08-25 Saisei Pharma Co., Ltd. Pharmazeutische zusammensetzung enthaltend ein verarbeitetes produkt aus bovinem kolostrumenzym
CN106456813B (zh) * 2014-04-15 2020-06-30 勃林格殷格翰国际公司 在制造生物制品期间连续灭活病毒的方法、装置和系统
WO2016194914A1 (ja) * 2015-06-01 2016-12-08 再生ファーマ株式会社 乳酵素処理物、その製造方法、組成物および製品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
WO1991015770A1 (en) * 1990-04-11 1991-10-17 The General Hospital Corporation Therapeutic uses of actin-binding compounds
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein

Also Published As

Publication number Publication date
JP2005508892A (ja) 2005-04-07
AU2002321012B2 (en) 2008-07-24
CA2456843A1 (en) 2003-02-27
ES2305272T3 (es) 2008-11-01
DE60226327T2 (de) 2009-07-09
ATE393780T1 (de) 2008-05-15
DK1419177T3 (da) 2008-08-25
WO2003016348A2 (en) 2003-02-27
WO2003016348A3 (en) 2004-03-04
EP1419177B1 (de) 2008-04-30
EP1419177A2 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
ATE130365T1 (de) Bakterien transformiert mit expressionsplasmiden, die für den menschlichen neurothrophen wimper faktor (h-cntf) kodieren, ihre verwendung in der herstellung von h-cntf, antikörper gegen h-cntf und die anwendung von h-cntf in medizischer behandlung.
US10005823B2 (en) Peptides having effects on promoting wound healing, collagen production, angiogenesis, activation of immunocytes and applications thereof
ATE295176T1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
RU95110699A (ru) Устройство для обработки крови, озоновый генератор для производства озона, устройство для контакта газа и жидкости, способ инактивации вируса иммунодефицита человека в белковом материале
DE60226327D1 (de) Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
WO2006102933A8 (en) Preparation of autologous haematopoietic stem cells, the methods of production, cyropreservation and use for therapy of traumatic diseases of the central nervous system
ATE121424T1 (de) Hpth-fragment-(1-37), seine herstellung, dieses enthaltende arzneimittel und seine verwendung.
EP0376251A3 (en) An anticoagulant substance obtained from urine
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
Cowen et al. Functional outcomes after inpatient rehabilitation of patients with end-stage renal disease
Jacob et al. Quality control for the validation of extracorporeal photopheresis process using the Vilbert–Lourmat UV-A irradiation’s system
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
HU9401185D0 (en) Method and composition for determining the immunological activity of bioactive substances
Kwan et al. Rehabilitation of proximal humerus fractures: An environmental scan of Canadian physiotherapy practice patterns
DE60002552D1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
Olaniyan et al. Raw Cucumber (Cucumis sativus) Fruit Juice as Possible First-Aid Antidote in Drug-Induced Toxicity
HRP20140247T1 (hr) Cjepivo protiv raka
CN107183478A (zh) 一种葡萄汁处理装置
Jeon et al. Investigating effects of negative emotional states on the korean elderly's osteoarthritis prevalence
RU2489172C1 (ru) Способ проведения лечебного дискретного плазмафереза с экстракарпоральной модификацией эритроцитов и лейкоцитов индукторами интерферона, антиоксидантами и протекторами клеток
TW200741011A (en) Method for the diagnosis and treatment of cardiovascular diseases
Veludhandi et al. Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)
Lastovka et al. CASE OF ATYPICAL WARFARIN-INDUCED SKIN NECROSIS IN A CHILD WITH CONGENITAL HEART DISEASE
PH22020050169Y1 (en) Intravenous pharmaceutical form of isolated and purified antibodies for the prevention and treatment of covid-19 and related diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee